Scinai Immunotherapeutics Ltd (SCNI) has a current Price-to-Book (P/B) ratio of 0.50. Compared to its 3-year average P/B ratio of -0.30, the current P/B ratio is approximately -267.73% higher. Relative to its 5-year average P/B ratio of 4.49, the current P/B ratio is about -88.97% higher. Scinai Immunotherapeutics Ltd (SCNI) has a Forward Free Cash Flow (FCF) yield of approximately -245.33%. Compared to its 3-year average FCF yield of -274.19%, the current FCF yield is approximately -10.53% lower. Relative to its 5-year average FCF yield of -173.49%, the current FCF yield is about 41.41% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SCNI competitors is 0.00, providing a benchmark for relative valuation. Scinai Immunotherapeutics Ltd Corp (SCNI.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SCNI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SCNI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SCNI currently overvalued or undervalued?

What is Scinai Immunotherapeutics Ltd (SCNI) fair value?

SCNI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Scinai Immunotherapeutics Ltd (SCNI) is between to according to relative valuation method.

How does SCNI's valuation metrics compare to the industry average?

The average P/S ratio for SCNI's competitors is 0.00, providing a benchmark for relative valuation. Scinai Immunotherapeutics Ltd Corp (SCNI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Scinai Immunotherapeutics Ltd (SCNI) as of Mar 03 2026?

As of Mar 03 2026, Scinai Immunotherapeutics Ltd (SCNI) has a P/B ratio of 0.50. This indicates that the market values SCNI at 0.50 times its book value.

What is the current FCF Yield for Scinai Immunotherapeutics Ltd (SCNI) as of Mar 03 2026?

As of Mar 03 2026, Scinai Immunotherapeutics Ltd (SCNI) has a FCF Yield of -245.33%. This means that for every dollar of Scinai Immunotherapeutics Ltd's market capitalization, the company generates -245.33 cents in free cash flow.

What is the current Forward P/E ratio for Scinai Immunotherapeutics Ltd (SCNI) as of Mar 03 2026?

As of Mar 03 2026, Scinai Immunotherapeutics Ltd (SCNI) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Scinai Immunotherapeutics Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Scinai Immunotherapeutics Ltd (SCNI) as of Mar 03 2026?

As of Mar 03 2026, Scinai Immunotherapeutics Ltd (SCNI) has a Forward P/S ratio of 0.00. This means the market is valuing SCNI at $0.00 for every dollar of expected revenue over the next 12 months.

SCNI Valuation